Undisclosed KATP inhibitor / Cephagenix - LARVOL DELTA

Saniona-Cephagenix joint venture migraine program in vivo validated (Market Screener) - "Saniona...announced successful preclinical in vivo validation for treatment of migraine in the Cephagenix joint venture program....The drug candidates from the Cephagenix program are intended for acute migraine treatment with potential for preventive treatment in chronic migraine patients....The Cephagenix program is aimed at identifying subtype-selective ATP-sensitive potassium channel (KATP) inhibitors for the treatment of migraine. It has been demonstrated in the clinic that drugs which induce dilation of intracranial blood vessels may induce migraine attacks in migraineurs and a KATP channel activator, levcromakalim, is by far the most effective agent studied to date as inducer of migraine attacks. Based on this, KATP channels has been suggested to be a unifying mechanism for the induction of migraine pain, e.g by NO, CGRP and PACAP. This is also supported by the finding that blocking KATP channels in rodent models of migraine is an effective pain-reducing treatment."

Preclinical • CNS Disorders • Migraine